SCHEMBL3003773

SCHEMBL3003773

O=S(=O)(c1cccc(C(F)(F)F)c1)C1CCN(c2nc(-c3cc(F)cc(Cl)c3)cs2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.48
RAB9A P51151 7/20 0.45
SMN1; SMN2 Q16637 7/20 0.45
CTSS P25774 1/20 0.45
KDM1A O60341 1/20 0.44
NPC1 O15118 6/20 0.44
RORC P51449 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 2/20 0.40
KCNQ1 P51787 1/20 0.40
MAPT P10636 3/20 0.39
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 1/20 0.38
RAF1 P04049 1/20 0.38
BRAF P15056 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008360 0.96 AR (0.52) ARRAB9ASMN1; SMN2CTSSKDM1A
SCHEMBL3005719 0.94 AR (0.52) ARRAB9ASMN1; SMN2CTSSKDM1A
SCHEMBL3006105 0.90 SMN1; SMN2 (0.53) ARRAB9ASMN1; SMN2KDM1ANPC1
SCHEMBL3014973 0.90 RAB9A (0.48) ARRAB9ASMN1; SMN2CTSSNPC1
SCHEMBL3009367 0.89 KDM1A (0.56) ARRAB9ASMN1; SMN2CTSSKDM1A
SCHEMBL3011795 0.88 AR (0.50) ARRAB9ASMN1; SMN2CTSSKDM1A
SCHEMBL3006447 0.88 SMN1; SMN2 (0.46) RAB9ASMN1; SMN2KDM1ANPC1MEN1
SCHEMBL3014307 0.87 RAB9A (0.51) ARRAB9ASMN1; SMN2CTSSNPC1
SCHEMBL3013920 0.87 AR (0.52) ARRAB9ASMN1; SMN2CTSSKDM1A
SCHEMBL3017305 0.86 AR (0.56) ARRAB9ASMN1; SMN2CTSSKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885RAB9A 2943/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.